Tag Archives: h3 biomedicine

April, 2018

5 April
H3 Biomedicine’s First-in-Class Splicing Factor Modulator Shows Promise in Multiple Types of Cancer in Early-Stage Trial

CAMBRIDGE, Mass.–(BUSINESS WIRE)–H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of next-generation cancer medicines using its data science and precision chemistry product engine, announced today the publication of a comprehensive genomic landscape analysis illuminating the breadth, frequency and potential disease-driving significance of somatic mutations …
Share

21 April
H3 Biomedicine Extends Collaboration with Foundation Medicine to Develop Precision Therapies for Cancer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, today announced that is has extended its multi-year collaboration with Foundation Medicine, Inc. for the discovery and development of precision …
Share

23 February
Foundation Medicine and H3 Biomedicine Partner for Precision Medicine in Cancer

Today, Foundation Medicine, Inc. and H3 Biomedicine Inc. announced that they will collaborate to develop precision therapies for cancer. The companies said that they have entered a multi-year collaboration for the discovery and development of precision medicines in oncology, utilizing Foundation Medicine’s comprehensive genomic knowledgebase of more than 35,000 genomic …
Share